Prolonged survival of patients with breast cancer-related leptomeningeal metastases.

Émilie Le Rhun, Sophie Taillibert, Fahed Zaïri, Diane Pannier, Thomas Boulanger, Charles André, J.-L. Cazin, François Dubois, Jacques Bonneterre, Marc C. Chamberlain

PubMed · 2013 · 23 citations · 0 references

Concepts

Abstract

BACKGROUND/AIM: Prolonged overall survival (OS) has been reported for selected patients with leptomeningeal metastases (LM). The management and treatment of such patients is poorly-described. We report our experience on breast cancer (BC)-associated LM and patients with prolonged survival. PATIENTS AND METHODS: Eleven patients with BC and LM had an OS >12 months in which treatment is described. RESULTS: Combined intra-cerebro spinal fluid (CSF) and systemic treatment were administered until disease progression or toxicity in all but two patients. Involved-field radiotherapy was administered to two patients. Median OS in this selected cohort following LM diagnosis, was 21.0 (range=13-33.3) months. CONCLUSION: Prolonged OS but also prolonged responses can be observed in BC with LM. An individualized and multi-disciplinary approach is advised for the management of these patients.